<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Johnson & Johnson — News on 6ix</title>
<link>https://6ix.com/company/johnson-and-johnson</link>
<description>Latest news and press releases for Johnson & Johnson on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:03:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/johnson-and-johnson" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358b6878dffbe2df1000da.webp</url>
<title>Johnson & Johnson</title>
<link>https://6ix.com/company/johnson-and-johnson</link>
</image>
<item>
<title>FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)</title>
<link>https://6ix.com/company/johnson-and-johnson/news/fda-grants-priority-review-for-imaavyr-nipocalimab-aahu-as-the-potential-first-approved-treatment-for-people-living-with-warm-autoimmune-hemolytic-anemia-waiha</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/fda-grants-priority-review-for-imaavyr-nipocalimab-aahu-as-the-potential-first-approved-treatment-for-people-living-with-warm-autoimmune-hemolytic-anemia-waiha</guid>
<pubDate>Mon, 27 Apr 2026 12:03:00 GMT</pubDate>
<description>Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY® (nipocalimab-aahu),c confirming the urgent need for treatment options in warm autoimmune hemolytic anemia (wAIHA). Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions and shortens the FDA review timeline to approximately six month</description>
</item>
<item>
<title>FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia</title>
<link>https://6ix.com/company/johnson-and-johnson/news/fda-approves-caplytar-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/fda-approves-caplytar-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia</guid>
<pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
<description>Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) based on long-term data evaluating the safety and efficacy of CAPLYTA® (lumateperone) for the prevention of relapse in schizophrenia. The data further reinforces the long-term efficacy and tolerability of CAPLYTA® as the latest addition to Johnson & Johnson's leading portfolio of neuropsychiatric therapies.</description>
</item>
<item>
<title>IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)</title>
<link>https://6ix.com/company/johnson-and-johnson/news/imaavyr-nipocalimab-aahu-shows-over-two-years-of-sustained-disease-control-in-a-broad-population-with-generalized-myasthenia-gravis-gmg</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/imaavyr-nipocalimab-aahu-shows-over-two-years-of-sustained-disease-control-in-a-broad-population-with-generalized-myasthenia-gravis-gmg</guid>
<pubDate>Wed, 22 Apr 2026 12:05:00 GMT</pubDate>
<description>Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension (OLE) in a broad population of antibody-positive (including anti-AChR+a and anti-MuSK+b) adults with generalized myasthenia gravis (gMG) reinforcing the efficacy, sustained disease control and proven safety profile of IMAAVY® (nipocalimab-aahu). These data are among the seven abstracts Johnson & Johnson is presenting at the American Academy of Neurology (AAN) 2026 Meeting i</description>
</item>
<item>
<title>Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler</title>
<link>https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-announces-ce-mark-approval-for-the-new-ethicontm-4000-stapler</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-announces-ce-mark-approval-for-the-new-ethicontm-4000-stapler</guid>
<pubDate>Wed, 22 Apr 2026 08:00:00 GMT</pubDate>
<description>NEW BRUNSWICK, N.J., April 22, 2026--Johnson & Johnson announces that it has received European CE Mark approval for its new ETHICON™ 4000 Stapler.</description>
</item>
<item>
<title>[Latest] Global Surgical Drill Bits Market Size/Share Worth USD 540 Million by 2035 at a 5.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)</title>
<link>https://6ix.com/company/johnson-and-johnson/news/latest-global-surgical-drill-bits-market-sizeshare-worth-usd-540-million-by-2035-at-a-55percent-cagr-healthcare-foresights-analysis-outlook-leaders-report-trends-forecast-segmentation-growth-rate-value-swot-analysis</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/latest-global-surgical-drill-bits-market-sizeshare-worth-usd-540-million-by-2035-at-a-55percent-cagr-healthcare-foresights-analysis-outlook-leaders-report-trends-forecast-segmentation-growth-rate-value-swot-analysis</guid>
<pubDate>Tue, 21 Apr 2026 04:30:00 GMT</pubDate>
<description>[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Surgical Drill Bits Market size & share revenue was valued at approximately USD 316 Million in 2025 and is expected to reach USD 333 Million in 2026 and is expected to reach around USD 540 Million by 2035, at a CAGR of 5.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are DePuy Synthes (Johnson & Johnson)</description>
</item>
<item>
<title>National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others</title>
<link>https://6ix.com/company/johnson-and-johnson/news/national-advertising-division-finds-certain-acuvuer-oasys-max-claim-supported-recommends-modification-or-discontinuation-of-others</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/national-advertising-division-finds-certain-acuvuer-oasys-max-claim-supported-recommends-modification-or-discontinuation-of-others</guid>
<pubDate>Mon, 20 Apr 2026 14:48:00 GMT</pubDate>
<description>Following a challenge brought by Alcon, Inc., BBB National Programs’ National Advertising Division determined that Johnson & Johnson Vision Care, Inc. (JJVC) had a reasonable basis for the claim “MAX comfort. MAX clarity.” for its ACUVUE® Oasys Max 1-Day contact lenses, however, recommended that JJVC discontinue or modify its superiority and “2X” comparative claims.New York, NY, April 20, 2026 (GLOBE NEWSWIRE) -- Following a challenge brought by Alcon, Inc., BBB National Programs’ National Adver</description>
</item>
<item>
<title>MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)</title>
<link>https://6ix.com/company/johnson-and-johnson/news/meiragtx-announces-the-acquisition-of-botaretigene-sparoparvovec-bota-vec-for-the-treatment-of-x-linked-retinitis-pigmentosa-xlrp</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/meiragtx-announces-the-acquisition-of-botaretigene-sparoparvovec-bota-vec-for-the-treatment-of-x-linked-retinitis-pigmentosa-xlrp</guid>
<pubDate>Thu, 16 Apr 2026 11:10:00 GMT</pubDate>
<description>Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vec LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asse</description>
</item>
<item>
<title>Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%</title>
<link>https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-announces-64th-consecutive-year-of-dividend-increase-raises-quarterly-dividend-by-31percent</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-announces-64th-consecutive-year-of-dividend-increase-raises-quarterly-dividend-by-31percent</guid>
<pubDate>Tue, 14 Apr 2026 10:21:00 GMT</pubDate>
<description>NEW BRUNSWICK, N.J., April 14, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases.</description>
</item>
<item>
<title>Johnson & Johnson reports Q1 2026 results, raises 2026 outlook</title>
<link>https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-reports-q1-2026-results-raises-2026-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-reports-q1-2026-results-raises-2026-outlook</guid>
<pubDate>Tue, 14 Apr 2026 10:20:00 GMT</pubDate>
<description>NEW BRUNSWICK, N.J., April 14, 2026--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2026. "Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in</description>
</item>
<item>
<title>Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision</title>
<link>https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-showcases-new-clinical-data-for-tecnis-puresee-iol-at-ascrs-2026-demonstrating-excellent-contrast-sensitivity-and-extended-range-of-vision</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-showcases-new-clinical-data-for-tecnis-puresee-iol-at-ascrs-2026-demonstrating-excellent-contrast-sensitivity-and-extended-range-of-vision</guid>
<pubDate>Fri, 10 Apr 2026 12:00:00 GMT</pubDate>
<description>JACKSONVILLE, Fla., April 10, 2026--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision</description>
</item>
<item>
<title>Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe</title>
<link>https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-advances-pulsed-field-ablation-portfolio-with-the-launch-of-varipulse-pro-in-europe</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-advances-pulsed-field-ablation-portfolio-with-the-launch-of-varipulse-pro-in-europe</guid>
<pubDate>Tue, 07 Apr 2026 12:00:00 GMT</pubDate>
<description>IRVINE, Calif., April 07, 2026--Johnson & Johnson announced launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) portfolio.</description>
</item>
<item>
<title>ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis</title>
<link>https://6ix.com/company/johnson-and-johnson/news/icotydetm-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-oncedaily-pill-for-plaque-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/icotydetm-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-oncedaily-pill-for-plaque-psoriasis</guid>
<pubDate>Sat, 28 Mar 2026 14:00:00 GMT</pubDate>
<description>Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ (icotrokinra) in the treatment of patients with moderate-to-severe plaque psoriasis (PsO). ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.</description>
</item>
<item>
<title>Johnson & Johnson’s DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers</title>
<link>https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnsons-darzalexr-daratumumab-becomes-the-first-oncology-injectable-approved-for-administration-by-patients-or-caregivers</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnsons-darzalexr-daratumumab-becomes-the-first-oncology-injectable-approved-for-administration-by-patients-or-caregivers</guid>
<pubDate>Fri, 27 Mar 2026 10:31:00 GMT</pubDate>
<description>Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and innovation, continuing to transform multiple myeloma care BEERSE, BELGIUM, March 27, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted approval for a Type II variation to the labelling fo</description>
</item>
<item>
<title>Origin Announces HP Embalagens as Strategic Distributor for Sustainable PET Bottlecaps</title>
<link>https://6ix.com/company/johnson-and-johnson/news/origin-announces-hp-embalagens-as-strategic-distributor-for-sustainable-pet-bottlecaps-1</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/origin-announces-hp-embalagens-as-strategic-distributor-for-sustainable-pet-bottlecaps-1</guid>
<pubDate>Thu, 19 Mar 2026 20:01:00 GMT</pubDate>
<description>WEST SACRAMENTO, Calif. & SÃO PAULO, March 19, 2026--Origin Materials, Inc. ("Origin") (NASDAQ: ORGN, ORGNW), a technology company with a mission to enable the world’s transition to sustainable materials, announced a strategic distributor relationship with HP Embalagens, a leader in high-performance thermoformed packaging, for sustainable PET bottlecaps.</description>
</item>
<item>
<title>FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide</title>
<link>https://6ix.com/company/johnson-and-johnson/news/fda-approval-of-icotydetm-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/fda-approval-of-icotydetm-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide</guid>
<pubDate>Wed, 18 Mar 2026 11:49:00 GMT</pubDate>
<description>Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.1 ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.2</description>
</item>
<item>
<title>Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch</title>
<link>https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-drives-innovation-in-pulsed-field-ablation-with-peru-launch</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-drives-innovation-in-pulsed-field-ablation-with-peru-launch</guid>
<pubDate>Mon, 16 Mar 2026 15:00:00 GMT</pubDate>
<description>LIMA, Peru, March 16, 2026--Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atrial fibrillation. This incorporation represents a significant advance in the approach to cardiac arrhythmias, with benefits in terms of safety, precision, and procedural efficiency.1</description>
</item>
<item>
<title>Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer</title>
<link>https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-highlights-promising-first-in-human-erda-idrs-formerly-tar-210-results-in-intermediate-risk-non-muscle-invasive-bladder-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/johnson-and-johnson-highlights-promising-first-in-human-erda-idrs-formerly-tar-210-results-in-intermediate-risk-non-muscle-invasive-bladder-cancer</guid>
<pubDate>Fri, 13 Mar 2026 16:35:00 GMT</pubDate>
<description>Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (FGFR) alterations. The study met its primary safety endpoint and demonstrated complete and durable responses in patients with recurrent intermediate-risk</description>
</item>
<item>
<title>Rybrevant (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/johnson-and-johnson/news/rybrevant-johnson-and-johnson-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/rybrevant-johnson-and-johnson-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 13 Mar 2026 16:31:00 GMT</pubDate>
<description>Key opportunities include increasing demand for personalized cancer therapies, growth in genomic testing, innovation in targeted treatments for NSCLC, and expansion of combination regimens. Strong potential lies in enhancing antibody-based solutions and establishing localized biologics manufacturing to offset tariff impacts.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Rybrevant Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarke</description>
</item>
<item>
<title>Zabdeno (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/johnson-and-johnson/news/zabdeno-johnson-and-johnson-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/zabdeno-johnson-and-johnson-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 13 Mar 2026 12:02:00 GMT</pubDate>
<description>Key opportunities in the Zabdeno market include increasing investment in outbreak preparedness, growing focus on next-gen vaccines, expanding global immunization, and strengthening vaccine partnerships. Region-specific challenges like tariffs spur local manufacturing, potentially enhancing supply chain resilience.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Zabdeno Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offe</description>
</item>
<item>
<title>Tecvayli (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/johnson-and-johnson/news/tecvayli-johnson-and-johnson-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/johnson-and-johnson/news/tecvayli-johnson-and-johnson-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 13 Mar 2026 11:30:00 GMT</pubDate>
<description>Key market opportunities include expanding next-gen immuno-oncology and personalized therapies, increased multiple myeloma prevalence fueling demand for Tecvayli, rising investment in cancer research, and growing adoption of bcma-targeted and bispecific antibody treatments. Additionally, growing regional biologics manufacturing presents opportunities amid tariff challenges.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Tecvayli Market Report 2026: Epidemiology, Pipeline Analysis, Market Insight</description>
</item>
</channel>
</rss>